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The Ability to Look: Management of Breast
Disease in the Democratic Republic of the
Congo Using Smart Ultrasound Technology
Ronda Henry-Tillman, MD, FACS, Mathew Kabongo, MD, Jonathan Laryea, MD, FACS, Leeya Pinder, MD,
Rebecca Bittenbinder, MD, Geoffrey Osgood II, MD, Maya Hicks, BA, Michael Hicks, MD,
Groesbeck Parham, MDBACKGROUND: The vast majority of women with breast cancer in sub-Saharan Africa present with advanced
stage disease, due primarily to the lack of opportunities for early detection and treatment. As
part of a larger effort to increase access to diagnostic and therapeutic services for women’s
cancers in the Democratic Republic of Congo (DRC), we implemented a curriculum to train
the local workforce and a program to build the supportive infrastructure for the diagnosis and
treatment of breast cancer at a private sector health facility (Biamba Marie Mutombo Hos-
pital) in Kinshasa.
STUDY DESIGN: After onsite trainings in the DRC by a US breast surgeon (RT), Congolese surgeons, general
physicians, physician assistants, and nurses used the Phillips Lumify smart-phone ultrasound
device to perform and interpret the results of whole breast ultrasound on symptomatic
women. Surgeons were trained to perform ultrasound-guided core needle biopsy on those
who met the criteria for tissue diagnosis, after which they trained nurses to do the same.
RESULTS: Over 3 years, 5,211 patients were identified as having a breast abnormality on clinical breast
examination. Ultrasound abnormalities were noted in 1,493 (27%) patients, of which 632
(42%) met the criteria for ultrasound-guided core needle biopsy or fine needle aspiration.
Pathology reports were available on 368 (58%) patients who underwent biopsy, of which 164
were malignant and 204 benign.
CONCLUSIONS: We demonstrated how the “ability to look” using smart technology can be successfully used
to augment clinical breast exam and triage patients for biopsy in a resource-constrained
African setting. (J Am Coll Surg 2021;232:636e640.  2020 by the American College of
Surgeons. Published by Elsevier Inc. All rights reserved.)Disclosure Information: Nothing to disclose.
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72205. email: henryrondas@uams.eduWorldwide, breast cancer is diagnosed in more than 2
million women and is responsible for more than
521,000 deaths, annually. In Africa, it is the most
commonly diagnosed cancer and the second leading cause
of cancer-related death.1,2 It disproportionately affects
young women in low to middle income countries
(LMIC), with 23% of new cases occurring in women
15 to 49 years of age vs 10% in high-income countries.3
While screening mammography combined with high
quality diagnostics and management (surgery, hormonal
therapy, biologics, chemoradiation) have significantly
improved disease outcomes in high income countries,
such services are scarce in LMICs.4
In low-income settings, such as the DRC, the barriers




¼ American College of Radiology Breast Imaging
Reporting and Data System
BMMH ¼ Biamba Marie Mutombo Hospital
CBE ¼ clinical breast exam
DRC ¼ Democratic Republic of the Congo
LMIC ¼ low to middle income countriesSome of these obstacles include, but are not limited to,
underfunding, workforce shortages, and fragmented clin-
ical infrastructure (eg ill-equipped healthcare facilities,
unreliable supply chains, insufficient laboratory services,
inadequate anesthesia support and blood banking capac-
ity, lack of cancer data bases/registries, and weak systems
for maintenance and repair). In such environments, ultra-
sound may be the best approach to breast evaluation given
its relative lower costs, the fact that breast lesions and can-
cers in this population of women tend to occur earlier,
when breasts are denser, and consensus guideline recom-
mendations that breast masses should generally undergo
diagnostic evaluation with ultrasound to distinguish their
nature.5 Recent developments in ultrasound technology
and portability, the incorporation of ultrasound training
into the curriculum of healthcare workers caring for
women with breast disease, and the use of percutaneous
core biopsy device have all been essential in advancing
the care of women who present with breast symptom-
atology. In this manuscript, we describe the use of
ultrasound-based visualization of the breasts with portable
smart technology in the DRC, how it was taught to
healthcare providers, and its implementation to augment
clinical breast exam (CBE) in symptomatic women.
METHODS
In 2017, a breast care clinic was established at the Biamba
Marie Mutombo Hospital (BMMH), a private healthcare
facility in the capital city of Kinshasa, in the Democratic
Republic of Congo (DRC). Women screened for cervical
cancer in a newly opened cervical cancer prevention clinic
in the same facility were asked about breast symptoms and
their willingness to have a CBE. Those answering in the
affirmative underwent a CBE by trained Congolese cervi-
cal cancer screening nurses. If discovered to have abnor-
malities (masses, thickening, new onset asymmetry,
pain, nipple discharge, axillary adenopathy, etc) they
were referred to the newly established breast clinic for
further evaluation with breast ultrasound. Ultrasound
was performed with the Phillips Lumify app on a smart
device (phone or tablet) with a specialized linear trans-
ducer, effectively converting the smart device into anultrasound machine (Fig. 1).6 Women with suspicious le-
sions on ultrasound underwent ultrasound-guided core
needle biopsy. All procedures were performed by Congo-
lese healthcare workers, including nurses, physician assis-
tants, and surgeons, initially under the on-site mentorship
of a US breast surgeon (master trainer). Core biopsy spec-
imens were sent to a private pathology laboratory for his-
tologic examination. Trainee competency was evaluated
using direct observation and concordance measurements
between ultrasound impressions and pathologic diagnosis.
Training
In alignment with the approved curriculum, BMMH
physicians, nurses, and physician assistants were trained
in the following areas: breast self-awareness; CBE; smart
phone and traditional breast ultrasound; axillary node
ultrasound for the evaluation of suspicious axillary nodes;
ultrasound-guided fine needle aspiration, and ultrasound-
guided core needle biopsy of breast masses. The training
was conducted by a senior US surgeon with expertise in
ultrasound technology, teaching breast diagnostics, and
surgical treatment of breast diseases. The curriculum
included basic physics and principles of ultrasound.7
Detailed instructions and scanning techniques were per-
formed on both live and phantom breast models. Detailed
review consisted of instructions on recognition of the
characteristics of ductal anatomy, normal breast paren-
chyma, benign vs malignant focal breast masses, and axil-
lary nodal anatomy.
The American College of Radiology Breast Imaging
Reporting and Data System (BI-RADS) was used as a
part of the training curriculum.8 BI-RADS takes into ac-
count the shape of breast masses, their orientation,
appearance of the margins, their echogenicity, posterior
features, and other associated findings. All patients who
underwent ultrasound and were found to have masses
were evaluated using BI-RADS to help determine man-
agement. If an abnormality was solid with any indetermi-
nate characteristic (taller than wide, lobulated borders, or
septate), the patient was consented for a spring-loaded
core biopsy. If a mass was anechoic with smooth borders,
it was classified as cystic and aspirated. Lesions classified as
BI-RADS 4 or 5 were biopsied, as were lesions classified as
indeterminate.
Percutaneous core needle biopsy was demonstrated on
phantom models, with emphasis on proper alignment of
the linear transducer for biopsy. The hand-held, spring-
loaded core biopsy device was placed in orientation
with the transducer to allow the needle to be seen parallel
to the transducer. Using sterile procedures, local anes-
thesia (1% lidocaine based on patient weight) was per-
formed followed by a small puncture incision with a
Figure 1. (A) Phillips Lumify Tele-Ultrasound Linear Ultrasound Transducer Probe; (B) Smartphone Enabled
Ultrasound demonstrating image quality with both smart pad and smart phone.#11 scalpel blade. This was followed by the insertion of a
14 G core needle (Fig. 2) into the breast under ultra-
sound guidance, after which 5 core biopsies were
obtained.
After completion of the training program, the local
clinical team was examined and checked off on the ability
to demonstrate their understanding of the physics and
principles of breast ultrasound and scanning techniques.
This included recognition of normal and abnormal find-
ings as well as demonstrating the ability to recognize and
aspirate fluid collections (cyst or seroma) and how to
perform a percutaneous biopsy using the spring-loaded
device. Detailed review of pathology and its implications
were evaluated and correlated with the clinical decision-
making. Trainees were required to describe concordance
and discordances in regard to ultrasound findings andFigure 2. Disposable (top) and (bottom) reusable 14 G percuta-
neous spring-loaded biopsy devices.pathologic results. Specific emphasis was placed on this
understanding of concordance, defined as results of pa-
thology consistent with interpretation of image findings.
If core biopsy results were benign or malignant and ultra-
sound findings were benign or malignant, respectively,
that was considered concordant. If cases of benign pathol-
ogy in the face of suspicious ultrasound findings, trainees
were instructed to perform an excisional biopsy.Trainee proficiency
Data were collected and analyzed to assess the ability of
the clinical team to effectively use the technology. This
was performed using proctor assessments during quarterly
visits of the master trainer, from 2017 to 2020. Additional
evaluations included self-assessments, how well trainees
retained knowledge from quarter to quarter, how well
the clinical team used the technology (Figs. 3, 4) and
(Table 1), as indicated by number of ultrasounds per-
formed, number of biopsies and descriptions of findings,Figure 3. Use by of ultrasound and biopsy by year, 2018 to
August 2020.
Figure 4. Data tree.
Table 2. Concordance of Ultrasound with Pathology
Variable Ultrasound, n Pathology, n Concordance, %
Benign 141 141 100
Malignant 91 94 97understanding the technical correlation, and concordance
between ultrasound impressions and biopsy.RESULTS
From April 2017 to August 2020, 5,211 patients were
identified as having a breast abnormality on CBE. Ages
ranged from 6 to 86 years; median age was 42.0
(14.1) years. Ultrasound abnormalities were noted in
1,493 (27%) patients, of whom 632 (42%) met the
criteria (indeterminate cystic lesion, solid or suspicious
masses) for ultrasound-guided core needle biopsy or fine
needle aspiration (Fig. 2). Pathology reports were avail-
able on 368 (58%) of those who underwent biopsy,
164 of which were malignant and 204 benign (Fig. 4).
The majority (approximately 90%) of the cancers were
advanced (TNM stages 3 and 4). The remainder were
stage 2. Approximately half (51%) of the malignancies
were ductal carcinomas. The benign lesions were mostlyTable 1. Number of Biopsies and Abnormalities by Year




Total 632 1,493fibrocystic masses and fibroadenomas. Surgical procedures
consisted of 183 lumpectomies, 58 modified radical mas-
tectomies, and 45 axillary lymph node dissections. All
cancer cases were referred to the newly developed chemo-
therapy unit at BMMH for evaluation. The concordance
rate for ultrasound imaging and pathology was 97% (91
of 94) for cancer and 100% (141 of 141) for benign
lesions (Table 2).
DISCUSSION
The ability to examine the breast using sound waves
(“the ability to look”), then use the various findings to
distinguish between normal breast tissue, common
artifacts, and benign and malignant lesions is critical
to appropriate decision-making, especially in highly
resource-constrained environments, like the DRC, where
pathology services are severely limited. This capability,
combined with the new (smart device/phone or tablet
apps), affordable (cost < $10,000), and more portable
(weight < 136 grams) ultrasound devices makes it even
more applicable as a tool in the clinical management of
patients with breast disease in LMICs. As of 2020, almost
90% of all cell phones and smart devices on the African
continent use the Android operating system.9 Therefore,
for any smart technology to be of use in this region of
the world, and similar environments, it should be capable
of integration within this type of system.
Over time, as their clinical experience accumulated, the
clinical team at BMMH gained greater competency using
the ultrasound smart technology device, as demonstrated
in Figs. 3 and 4. Clinical competency, defined as the iden-
tification of indicated lesions to be biopsied and the abil-
ity to safely and effectively perform core needle biopsies,
was reached early in the training. Our concordance data
(Table 2) of 97% for malignant and 100% for benign le-
sions are consistent with the data generally quoted in the
literature.10 This is of utmost importance because it allows
an accurate assessment without the cumbersome use of
large, expensive, nonportable ultrasound equipment. It
is also of great use in settings in which the “gold standard”
of pathology is either nonexistent, unaffordable, or
severely limited, and physicians are forced to rely on clin-
ical impression alone to determine how breast lesions are
managed.
The best chance for optimal outcomes in patients with
breast cancer is early identification and diagnosis coupled
with high quality treatment. In most LMICs, surgeons are
not trained in ultrasound technology and therefore rely on
radiologists for all diagnostic studies. The type of curric-
ulum we implemented at BMMH allows the surgeon to
become the primary diagnostician and interventionist,
making the workup and treatment of breast diseases
more timely and efficient. This is important in LMICs,
where women sometimes have to travel long distances
to reach healthcare facilities, and where it has been shown
that delay in diagnosis is associated with worse
outcomes.11,12
There were challenges in our program. First, the lack of
in-house pathology services resulted in the use of outside
private labs that were cost prohibitive to many patients.
This led to 20 missing pathology reports. Second, the dif-
ficulty of procuring a steady supply of core needle biopsy
guns into the country, for there was no suppler in the
DRC; and third, the training literature for the Lumify
App platform was not in the French language. BMMH
has partnered with the American Society of Clinical
Pathologist to develop a pathology laboratory at the hos-
pital to overcome this impediment. We were able to find a
local translator to translate the Lumify App instructions
into French.CONCLUSIONS
The “ability to look” into the substance of the breast using
sound waves has many applications in the diagnosis and
management of breast diseases, including cancer. Breast
ultrasound, when used as an adjunct to physical examina-
tion, can be used to differentiate benign from malignant
lesions and to allow for and direct clinical interventions.
We combined its use with percutaneous core needle bi-
opsy as the basic components of a platform for the evalu-
ation symptomatic women in a resource-constrained
environment. When integrated as a component of our
innovative training curricula, it became a relevant training
and patient management platform that is both affordable
and scalable.
Author Contributions
Study conception and design: Henry-Tillman, Kabongo,
Laryea, Pinder, Bittenbinder, Osgood II, Maya Hicks,
Michael Hicks, Parham
Acquisition of data: Pinder, Kabongo, Maya Hicks
Analysis and interpretation of data: Henry-Tillman,
Kabongo, Laryea, Pinder, Bittenbinder, Osgood II,
Maya Hicks, Michael Hicks, Parham
Drafting of manuscript: Henry-Tillman, Kabongo, Lar-
yea, Pinder, Bittenbinder, Osgood II, Maya Hicks,
Michael Hicks, ParhamCritical revision: Henry-Tillman, Kabongo, Laryea,
Pinder, Bittenbinder, Osgood II, Maya Hicks, Michael
Hicks, Parham
Acknowledgment: The authors wish to acknowledge the
Dikembo Mutombo Foundation, the Howard G Buffet
Foundation, and the Friends of Africa, Inc.
REFERENCES
1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and
mortality and epidemiology of breast cancer in the world.
Asian Pac J Cancer Prev 2016;17[sup 3]:43e46.
2. Tfayli A, Temraz S, Mrad RA, Shamseddine A. Breast cancer
in low- and middle-income countries: an emerging and chal-
lenging epidemic. J Oncol 2010;2010:1e5.
3. Freedman L, Barchana M, Al-Kayed S, et al. A comparison of
population-based cancer incidence rates in Israel and Jordan.
Eur J Cancer Prev 2003;12:359e365.
4. AmericanCancer Society. Breast cancer facts and figures. Available
at: https://www.cancer.org/content/dam/cancer-org/research/
cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-
cancer-facts-and-figures-2019-2020.pdf. Accessed September 22,
2020.
5. Dempsey PJ. The history of breast ultrasound. J Ultrasound
Med 2004;23:887e894.
6. Lumify transducers (probes) & accessories: Philips Healthcare.
Philips. Available at: https://www.usa.philips.com/healthcare/
sites/lumify/products-accessories. Accessed November 12, 2020.
7. Staren ED, Knudson MM, Rozycki GS, et al. An evaluation of
the American College of Surgeons’ ultrasound education pro-
gram. Am J Surg 2006;191:489e496.
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V Suzanne Klimberg, MD, PhD, MSHCT, FACS
Galveston, TX
I enjoyed reading the Congo experience with ultrasound giving
frontline practitioners the “ability to look.”1 It certainly has
increased the ability to find cancer in this relatively young
